P reeclampsia is a serious hypertensive pregnancy disorder complicating 2% to 5% of all pregnancies. Preeclampsia is characterized by hypertension and proteinuria after 20 weeks of gestation. Women with a history of preeclampsia are at increased risk to develop early onset cardiovascular disease (CVD) later in life when compared with women who had an uneventful pregnancy.
P reeclampsia is a serious hypertensive pregnancy disorder complicating 2% to 5% of all pregnancies. Preeclampsia is characterized by hypertension and proteinuria after 20 weeks of gestation. Women with a history of preeclampsia are at increased risk to develop early onset cardiovascular disease (CVD) later in life when compared with women who had an uneventful pregnancy. 1 Therefore, in 2011, the American Heart Association added preeclampsia to the list of risk factors for developing CVD. 2 The mechanistic explanation for the link between preeclampsia and later CVD remains to be elucidated. 3 Numerous studies demonstrated increased prevalence of cardiovascular risk factors after a pregnancy complicated by preeclampsia. [4] [5] [6] Most formerly preeclampsia women, however, do not demonstrate a traditional cardiovascular risk profile within the first years after preeclampsia. 6 Yet, when compared with healthy parous controls, the relative risk of developing chronic hypertension within 15 years after preeclampsia is estimated 3.7 (95% confidence interval, 2.7-5.5). 1 This observation indicates that a subset of normotensive formerly preeclampsia women is at risk to develop hypertension within the first years after the affected pregnancy. It is conceivable that these formerly preeclampsia women have subtle or latent abnormalities that could explain the increased cardiovascular risk after pregnancy.
Low plasma volume (PV) is considered to reflect latent hypertension, 7 and normotensive formerly preeclampsia women with low PV (LPV) are prone to develop recurrent hypertensive disease in subsequent pregnancy. 8 Whether PV status also relates to chronic hypertension after a pregnancy complicated by preeclampsia has never been studied before. We hypothesized that LPV status in normotensive formerly preeclampsia women predisposes to the development of hypertension. In this longitudinal study, we additionally studied how the traditional cardiovascular and metabolic risk profiles evolve over time after a preeclamptic pregnancy.
Abstract-Formerly preeclamptic women are at risk for cardiovascular disease. Low plasma volume may reflect latent hypertension and potentially links preeclampsia with chronic cardiovascular disease. We hypothesized that low plasma volume in normotensive formerly preeclamptic women predisposes to hypertension. We longitudinally studied n=104 formerly preeclamptic women in whom plasma volume was measured 3 to 30 months after the preeclamptic pregnancy. Cardiovascular variables were assessed at 2 points in time (3-30 months postpartum and 2-5 years thereafter). Study population was divided into low plasma volume (≤1373 mL/m 2 ) and normal plasma volume (>1373 mL/m 2 ). Primary end point was hypertension at the second visit: defined as ≥140 mm Hg systolic or ≥90 mm Hg diastolic. Secondary outcome of this study was change in traditional cardiovascular risk profile between visits. Variables correlating univariately with change in blood pressure between visits were introduced in regression analysis. Eighteen of 104 (17%) formerly preeclamptic women who were normotensive at first visit had hypertension at second evaluation 2 to 5 years later. Hypertension developed more often in women with low plasma volume (10/35 [29%] ) than in women with normal plasma volume (8/69 [12%]; odds ratio, 3.2; 95% confidence interval, 1.4-8.6). After adjustments, relationship between plasma volume status and subsequent hypertension persisted (adjusted odds ratio, 3.0; 95% confidence interval, 1.1-8.5). Mean arterial pressure at second visit correlated inverse linearly with plasma volume (r=−0.49; P<0.01). Initially normotensive formerly preeclamptic women have 17% chance to develop hypertension within 5 years. Women with low plasma volume have higher chance to develop hypertension than women with normal plasma volume. Clinically, follow-up of blood pressure seems warranted in women with history of preeclampsia, even when initially normotensive. (Hypertension.
Methods

Subjects
In this study, we used a database of women with a history of preeclampsia (n=386) who had been tested twice in the years after their preeclamptic pregnancy. We selected women who were normotensive and apparently healthy at their first assessment 3 to 30 months post partum. Reassessment of the cardiovascular and metabolic risk profile took place prospectively 2 to 5 years after the initial assessment.
Preeclampsia was defined according to the criteria set by the International Society for the Study of Hypertension in Pregnancy 9 (systolic blood pressure [SBP] ≥140 mm Hg or diastolic BP [DBP] ≥90 mm Hg, measured twice, >6 hours apart, plus consistent proteinuria of ≥300 mg in 24 hours or protein:creatinine ratio >30 g/ mol after gestational week 20 in previously normotensive women). All formerly preeclampsia women included in the database were of Northern European Ancestry and completed a cardiovascular evaluation 3 to 30 months after their complicated pregnancy (visit 1) in the period January 2008 to December 2010. A follow-up program was started in 2011, and all women were invited for reassessment of their cardiovascular risk profile (visit 2) at 2 to 5 years after the first visit. For this study, we compared data from both assessments.
Both cardiovascular evaluations were performed in the nonpregnant state at least 3 months post partum, and all women had discontinued breastfeeding for at least 4 weeks. Women who were hypertensive at the first assessment were excluded. Hypertension was defined as SBP ≥140 mm Hg and DBP ≥90 mm Hg, or when taking antihypertensive drugs. Also excluded from analysis were women diagnosed with diabetes mellitus (type 1 or 2) or autoimmune diseases at the first visit. Women were only invited for the second cardiovascular assessment when at least 2 years after the initial evaluation.
The study was approved by the Medical Ethics Committee of the Radboud University Medical Centre Nijmegen (CMO 2010/245). All women gave written informed consent. This study adhered to the principles of the declaration of Helsinki.
Experimental Procedures
PV was measured only during visit 1, and not during visit 2. All other measurements were performed at both visits according identical protocol.
The PV (milliliter) indicates the total blood volume minus the cellular volume and was measured using the golden standard method: the iodine 125 albumin indicator dilution technique ( 125 I-HSA). During the measurement, women were in semisupine position on a comfortable bed. An 18-gauge intravenous catheter was inserted in the left antecubital vein for repetitive blood sampling. A standardized dose (0.2 MBq) of 125 I-HSA was injected intravenously in the right antecubital vein. Every 10 minutes, a venous blood sample was taken from the contra lateral intravenous catheter until 40 minutes after administration of the 125 I-HSA. Blood samples were analyzed using a gamma counter. PV was calculated by dividing the total injected radioactivity by the virtual volume-specific radioactivity at time zero, as described elsewhere. 8 PV was normalized for body surface area (PV, mL/m 2 ). PV was categorized into 2 groups based on measurements in control group: LPV ≤1373 mL/m 2 corresponding to less than or equal to −1 SD below mean PV in control subjects; and normal PV >1373 mL/m 2 equivalent to greater than −1 SD of controls.
At each visit, a detailed history of complaints including family history was taken. A positive family history of CVD, hypertension, or diabetes mellitus was defined as having at least 1 first-degree relative who was diagnosed with any of these conditions before the age of 65 years. All measurements were performed after an overnight fast and scheduled between day 3 and 11 of the menstrual cycle to minimize possible endocrine influences of the sex hormones on the cardiovascular system. 10 The measurements started at 8.00 am to prevent diurnal variations between measurements in a temperature controlled room (≈22°C) with external disturbances kept to a minimum. Participants were instructed to abstain from strenuous physical activity in the 24 hours before testing. Participants collected urine for 24 hours preceding the measurements. The 24-hour urine sample was assayed for albumin, protein, and creatinine to establish (micro) albuminuria corrected for creatinine output (g/mol creatinine) and total protein concentration (g/24 h; Aeroset; Abbot Laboratories, IL). Body weight and height were measured. Body mass index (kg/m 2 ) was calculated as body weight (kg) divided by squared height (m 2 ), body surface area (m 2 ) as 0.007184·height (cm) 0.725 ·weight (kg) 0.425 .
11
After 30 minutes of rest in semisupine position, BP and heart rate were measured oscillometrically (Dinamap, Vital Signs Monitor 1846; Critikon, Tampa, FL) in this half-sitting position, with the cuff at the right upper arm at heart level at 3-minute intervals for a period of 30 minutes with a cuff size recommended for the arm circumference (13.5×30.7 cm if arm circumference ranged between 27.5 and 36.5 cm or 17×38.6 cm if arm circumference ranged between 35.5 and 46 cm). We recorded SBP (mm Hg), DBP (mm Hg), mean BP (MBP, mm Hg), and heart rate (bpm) and used the median values of 9 consecutive measurements for analysis. Hypertension was defined as SBP ≥140 mm Hg and DBP ≥90 mm Hg.
Venous blood samples were taken from an antecubital vein and analyzed for glucose, insulin, lipid profile, and creatinine concentration (Aeroset; Abbot Laboratories). The Homeostatic Model Assessment score was used to calculate the level of insulin resistance with the following equation: (fasting glucose×fasting insulin)/22.5. 
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Statistics
Normally distributed data are presented as mean±SD, non-normally distributed data as medians with interquartile range. Differences between groups were tested using ANOVA statistics, Wilcoxon ranksum, or χ 2 tests where appropriate. Associations of variables with change in MBP between assessments were explored using univariate analysis (Spearman ρ). All variables with significant association (P<0.05) with change in BP between 2 assessments were subsequently included in a multivariate regression model. For the multivariate analyses, we used stepwise backward elimination on the basis of Wald test, using a P value of 0.05 for elimination of variables. The normal PV group was used as statistical reference group. Group-size calculation was estimated based on combining the observed occurrence of hypertension within 12 months (25%) 9 and within 15 years (52%) 1 after preeclampsia. It was estimated that 12% of initially normotensive formerly preeclamptic women develop de novo hypertension within 5 years. To compensate for possible errors in the estimation, we based our sample size calculation on a prevalence of only 10% chronic hypertension in women 2 to 5 years after a pregnancy complicated by preeclampsia. In the general Dutch population, the prevalence of hypertension in women of similar age is 3.7%. Using this percentage as a reference than the study population would need at least 98 subjects to detect 10% chronic hypertension with a power of 80% and α of 0.05. All computations were performed using SPSS version 20.0.
Results
From 386 formerly preeclampsia women who completed a cardiovascular evaluation after a preeclamptic pregnancy (visit 1), 104 (27%) women were eventually included in the final analysis. As shown in Figure 1 , 183 women met the exclusion criteria (Figure 1 ). The remaining 203 normotensive apparently healthy formerly preeclampsia women were eligible and, therefore, invited for the second assessment (visit 2). At time of analysis, 99 of the 203 (49%) eligible women were lost to follow-up.
The first cardiovascular and metabolic assessment was at a median of 7 months after the index pregnancy (interquartile range, 6-11 months) and the median interval between visits was 47 months (interquartile range, 42-53 months). Consequently, the median interval between delivery and second assessment was 55 months (interquartile range, 50-65).
The characteristics of the 104 women included in the final analysis are shown in Table 1 . Women who were eligible, but not available at follow-up (n=99), were less often primiparous (79% versus 94%), delivered at a later gestational age (35 versus 33 weeks) of heavier infants (2149 versus 1945 g) and had less often a positive first-degree family history for hypertension (54% versus 63%) and CVD (25% versus 42%). Thirty-five of the 104 included women (34%) had LPV at the first visit. Table 2 shows the characteristics of the 104 formerly preeclampsia women who were normotensive at the first visit and either stayed normotensive (n=86; 83%) or developed hypertension (n=18; 17%) 2 to 5 years later. Women who developed hypertension when compared with women who remained normotensive were comparable for all measured variables at the first visit except for a significantly lower mean PV (1322 versus 1509 mL/m 2 ). In women who stayed normotensive 25 of 86 (29%) had LPV, in contrast to 10 of 18 (56%) women who developed hypertension (P=0.03). Average SBP, MBP, and DBP were slightly, but not significantly, higher in women destined to develop hypertension (123 versus 119; 92 versus 88 and 75 versus 72 mm Hg, respectively).
The majority of women in both groups had a second pregnancy between the 2 visits. Outcomes of these pregnancies were comparable although gestational hypertension in the next pregnancy tended to occur more often in women Table 3 ). When study group was divided based on PV status, chance of developing hypertension after preeclampsia was 10 of 35 (29%) in women with LPV status and 8 of 96 (12%) in women with normal PV status (odds ratio, 3.2; 95% confidence interval, 1.4-8.6; Table 4). When adjusted for possible confounders like family history for hypertension and DBP at first visit, the relationship between PV and developing hypertension after preeclamptic pregnancy persisted (adjusted odds ratio, 3.0; 95% confidence interval, 1.1-8.5).
Discussion
This study demonstrates that 1 of 6 (17%) formerly preeclampsia women who are normotensive at 3 to 30 months post partum develop overt hypertension within the subsequent 2 to 5 years. Women with LPV were more prone to develop hypertension than women with normal PV. LPV may, therefore, reflect a latent hypertensive profile that can become manifest within a few years after the preeclamptic pregnancy.
It has been well established that formerly preeclampsia women are at increased risk of developing CVD later in life. 1 It is hypothesized that preeclampsia and CVD share several common risk factors that may lead to expression of these disease entities at different times in a woman's life. 5, 6, [12] [13] [14] An alternative hypothesis is that preeclampsia itself may induce subclinical vascular and metabolic changes that in time increase the risk for overt hypertension and CVD later in life. Our study does not differentiate between these possible mechanisms. Irrespective of the underlying mechanism, a history of preeclampsia may identify women at risk for CVD early in life, thus offering a unique opportunity for timely screening and preventative strategies. 15 The prevalence of 17% hypertension in our study is markedly higher than the 3.7% prevalence of hypertension in the general population of Dutch women between 30 and 39 years. 16 Adding the excluded women who remained hypertensive after the preeclamptic index pregnancy (47/386; 12%)) the overall prevalence of hypertension after preeclampsia is comparable with the mean prevalence of 30% to 40% found in other studies in formerly preeclampsia women. 6, [17] [18] [19] [20] Our data show that a substantial proportion of women progressed within a few years from normotension to hypertension.
The exact cause of the phenotype LPV is currently unknown, but several explanations have been hypothesized. With two thirds of resting blood volume in the venous compartment, an actively constricted venous system might chronically reduces venous dimensions and (resting) elastic properties of the venous wall and thereby reducing its capacitance. An intrinsically small venous system, in line with the Barker hypothesis, might also account for the observed PV. Finally, PV may be functionally reduced as a result of hormonal misbalance. Recent studies have suggested a pathophysiological role of increased vasopressin levels in preeclampsia. 21 If vasopressin increases, one would expect higher PV levels unless the vasopressin is increased secondary to LPV status. In pregnancy, however, women who develop preeclampsia are not chronically underfilled because compensatory neurohumoral changes such as elevated renin, angiotensin, and aldosterone levels are lacking. 22 Whether neurohumoral changes contribute, either by cause or effect, to LPV status in the nonpregnant situation of formerly preeclamptic women is currently unknown. Therefore neurohumoral explanations for LPV cannot be completely excluded.
The mechanistic explanation for the relationship between LPV and the development of hypertension is hypothetical. One possible pathophysiological explanation could be that LPV status negatively affects cardiac preload, driving the sympathetic nervous system to compensate the reduced venous reserve. The resultant reduction in circulation time of the blood to pass the heart at each rotation will increase shear forces on the vascular endothelium, setting the stage for chronic hypertension. 7, 14, 23 Formerly preeclampsia women who developed hypertension gained more weight between the 2 visits and had higher fasting glucose levels at the second visit. This suggests a less healthy lifestyle in formerly preeclampsia women destined to develop hypertension. Lipid profile and microalbuminuria remained relatively stable in the first 5 years after the preeclamptic pregnancy, independent if women developed hypertension or not. This may indicate that short-term cardiovascular follow-up in normotensive formerly preeclamptic women should focus on aberrations in BP, body weight, and glucose metabolism and less on dyslipidemia or albuminuria.
Limitations
Generalizability of the study is limited because of several reasons. First, women with a positive family history of hypertension or CVD may have had an incentive to participate in our follow-up study. This may have resulted in an over-representation of women who are genetically more susceptible to develop hypertension at a young age. Also women lost to follow-up were more often multiparous and delivered at a later gestational age. Therefore, women with earlier onset preeclampsia, an indicator of more severe forms of preeclampsia, might be over-represented in our study group. Second, there was a considerable loss to follow-up, mainly because interval after the first assessment was not yet >2 years. Because group characteristics of included women were generally comparable with women lost to follow-up, we do not expect a large selection bias. Third, women who developed hypertension had more often a hypertensive pregnancy between the 2 assessments than women who remained normotensive. Although the second assessment was at least 3 months post partum to allow for hemodynamic recovery, we cannot rule out a possible overestimation of the BP because recovery may still continue thereafter. Pregnancy outcome, however, did not correlate with change in BP between visits, suggesting a nonsignificant impact on outcome. Follow-up period of maximally 5 years is relatively short for developing hypertension. Longer followup would likely influence the reported occurrence of hypertension in formerly preeclampsia women.
Perspectives
Monitoring of BP seems warranted in women with a history of preeclampsia, even in absence of hypertension in the first 2 years after pregnancy. It should be noted that the effects of structural cardiovascular and metabolic follow-up on clinical cardiovascular outcomes in this specific population are unknown. Nevertheless, based on the strong association between preeclampsia and future CVD, structured followup is often recommended. This may vary from follow-up in primary care or in more specialized cardiovascular risk management collaborations of care takers including perinatology, cardiology, and vascular internal medicine specialists. 7 Structured follow-up more likely secures regular surveillance of CVD risk factors and hypertension, in particular, with treatment according to national guidelines for CVD prevention in these women. Ideally, this should be coupled with primary prevention strategies focusing at lifestyle modifications (physical exercise, healthy diet, weight loss, and smoking cessation) to optimize maternal cardiovascular health. Lifestyle interventions have demonstrated to reduce cardiovascular risks substantially in various populations at risk for CVD. 24, 25 Aerobic exercise and diet prevent hypertension and excessive weight gain and reduce insulin resistance. 24 Interestingly, women are particularly motivated to change their lifestyle habits during pregnancy or the postpartum period to optimize outcomes of mother and child, and it is therefore considered an ideal timing to encourage primary prevention strategies.
26,27
Conclusions
One in 6 initially normotensive formerly preeclampsia women develop hypertension within the next 2 to 5 years. In these apparently healthy women, LPV correlates with increased risk to develop hypertension. Clinically, follow-up of BP seems warranted after a pregnancy complicated by preeclampsia, even in women who are initially normotensive. Prevalence, n/n (%) and OR of de novo hypertension at the second visit in women with a history of preeclampsia. Study population classified in 2 groups. Low plasma volume defined as <1373 mL/m 2 ; normal plasma volume as ≥1373 mL/m 2 . CI indicates confidence interval; and OR, odds ratio. *Adjustments for family history of hypertension (yes/no) and diastolic blood pressure (mm Hg) at the first visit were performed using backward multivariate regression analysis.
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